Congestive heart failure with right heart failure

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79